Background: In order to assess public health policies for the perinatal period, routinely produced indicators are needed for the whole population. In France, these indicators are used to compare the national public health policy with those of other European countries. French administrative and medical data (PMSI) are straightforward and reliable and may be a valuable source of information for research. This study aimed to measure the quality of PMSI data from three university health centers for core indicators in perinatal health.
Method: PMSI data were compared with medical files in 2012 from 300 live births after 22 weeks of amenorrhea, drawn at random from University Hospitals in Dijon, Paris and Nancy. The variables were chosen based on the Europeristat Project's core and recommended indicators, as well as those of the French National Perinatal survey conducted in 2010. The information gathered blindly from the medical files was compared with the PMSI data positive predictive value (PPV) and the sensitivity was used to assess data quality.
Results: Data on maternal age, parity and mode of delivery as well as the rates of premature births were superimposable for the two sources. The PPV for epidural injection was 96.2% and 94.3% for perineal tears. Overall, maternal morbidity was underdocumented in the PMSI, so the PPV was 100.0% for pre-existing diabetes, 88.9% for gestational diabetes and 100.0% for high blood pressure with a rate of 9.0% in PMSI and 6.3% in the medical files. The PPV for bleeding during labor was 89.5%.
Conclusion: To conclude, PMSI data are apparently becoming more and more reliable for two reasons: on one hand, the importance of these data for budgetary promotion in hospitals; on the other, the increasing use of this information for statistical and epidemiological purposes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.respe.2015.05.001 | DOI Listing |
Eur J Vasc Endovasc Surg
October 2024
Service de Biostatistiques et d'Information Médicale (DIM); CHU Dijon Bourgogne, Dijon, France; INSERM, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, Dijon, France; Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France.
Objective: This retrospective, nationwide cohort study aimed to compare peri-procedural stroke or death within 30 days of the procedure (PPSD30) in patients who underwent carotid endarterectomy (CEA) or carotid stenting (CAS).
Methods: This retrospective cohort study used data from the French hospital database PMSI. All patients who underwent CEA or CAS between 2010 and 2019 in France were included.
Arch Cardiovasc Dis
October 2024
Cardiology, Bichat Hospital, AP-HP, 75018 Paris, France; UMRS 1148, Inserm, 75018 Paris, France; Université Paris Cité, 75006 Paris, France.
Background: In patients with significant tricuspid regurgitation, cardiac magnetic resonance imaging (CMR) is the preferred method for the evaluation of right ventricular function and volumes. However validated thresholds are lacking.
Aim: The aim of this study was to evaluate CMR assessment of right ventricular volumes in patients with significant (moderate or severe) tricuspid regurgitation, and to define its association with outcomes.
BMC Urol
October 2024
Department of Urology, Nancy University Hospital, Vandoeuvre-lès-Nancy, 54500, France.
Background: Laparoscopic surgery is associated with a lower morbidity than open surgery. No recent data compared kidney cancer surgery in the French population using the National Health Insurance database (PMSI-MCO).
Aims: We explore and compare the surgical morbidity rates between laparoscopic and open laparotomy for kidney cancer.
Clin Transl Radiat Oncol
November 2024
Department of Urology CHRU Nancy, Brabois Hospital, 54000 Nancy, France.
Clin Transl Gastroenterol
December 2024
EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance, Saint-Denis, France.
Introduction: Trastuzumab deruxtecan (T-DXd) has been approved for human epidermal growth factor receptor 2-positive locally advanced or metastatic gastric and gastroesophageal junction (HER2+ mG/GEJ) cancer since July 2022 in France, through an accelerated approval. The aim of this study was to evaluate its real-world use.
Methods: We characterized T-DXd users treated for HER2+ mG/GEJ cancer using data from the French National Health Insurance database.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!